Visão geral da empresa
A biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel muscle activators and inhibitors, Cytokinetics, Incorporated targets the treatment of debilitating diseases within the United States market. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, positioning itself as a specialized developer of small molecule therapeutics like MYQORZO. As of the latest reporting period, the firm maintains a market capitalization of $8.10B, generates $88.04M in annual revenue, and employs a workforce of 673 individuals. These valuation and revenue figures indicate that despite being a private-market-cap sized entity relative to large-cap peers, the company commands significant investor attention, suggesting high expectations for the commercial success of its pipeline assets in the rare disease and cardiovascular therapeutic space.
Saúde financeira
The company reported a revenue of $88.04M for the trailing twelve months, yet recorded a net income of $-784,955,008 and an EBITDA of $-602,132,992, revealing a cost structure where operating expenses significantly exceed revenue generation. This substantial gap between the $88.04M in revenue and the negative net income highlights the typical R&D and commercialization burn rates inherent in the biotechnology sector during the pre-profitability phase. Free cash flow stands at $-379,618,752, indicating that the company is consuming cash to fund operations and growth initiatives rather than generating liquidity from current business activities. The gross margin is recorded at 0.0%, while the operating margin is -1004.6% and the profit margin is 0.0%, figures that collectively underscore the company's current inability to achieve profitability on a per-unit basis due to high fixed costs and research expenditures. The balance sheet presents a complex picture with $882.22M in cash available against $1.44B in total debt, suggesting a leveraged position that relies on future financing or cash flow generation to service obligations. Although the debt-to-equity ratio is listed as N/A, the absolute debt level relative to cash reserves implies a need for strategic capital management. The current ratio is 4.53, which indicates a robust short-term liquidity position capable of meeting immediate financial obligations despite the negative earnings environment. Return on Assets is -27.1%, reflecting the inefficient use of assets in generating positive returns in the current fiscal period, while Return on Equity is N/A due to the absence of attributable earnings for the calculation.
Avaliação de valorização
Valuation metrics for Cytokinetics, Incorporated reflect its stage of development, with a trailing P/E ratio of N/A and a forward P/E of -13.33, the latter implying that the market prices the stock based on anticipated future earnings rather than historical performance. The price-to-book ratio stands at -12.26, a metric that is atypical for established companies but common for biotech firms with significant intangible assets or research pipelines not fully captured on the balance sheet. The price-to-sales ratio is 92.01, a high multiple that suggests the market assigns substantial value to the company's revenue potential and the expected commercialization of its muscle activator therapies. Additionally, the EV/EBITDA is -14.38, which further emphasizes that traditional valuation multiples are not applicable in the conventional sense due to the negative earnings profile. In terms of trading range, the 52-week high is $70.98 and the 52-week low is $29.31, meaning the current market price fluctuates within a range that reflects significant volatility over the past year. The beta value is 0.48, indicating that the stock price tends to be less volatile than the broader market, moving with lower sensitivity to general market fluctuations compared to the average equity.
Growth & Income
Revenue growth year-over-year is recorded at 4.9%, while earnings growth is N/A, illustrating that the company is expanding its top line but has not yet achieved positive earnings to calculate year-over-year growth in profitability. The absence of a positive earnings growth rate implies that revenue expansion is currently being absorbed by operating costs rather than translating into bottom-line improvement. As a non-dividend payer, the company does not offer a dividend yield or a payout ratio, as the payout ratio is 0.0%, signaling that all available cash and potential earnings are retained to fund research, development, and commercialization efforts. This reinvestment strategy is standard for biotechnology companies aiming to bring novel muscle activators and inhibitors to market before returning capital to shareholders. The overall growth and income profile is characterized by revenue expansion in a high-growth therapeutic area, coupled with a lack of current income generation and a reliance on external capital or future cash flow generation to sustain operations and fund the development of potential treatments for debilitating diseases.